{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:32:50Z","timestamp":1777901570587,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ekir.2026.103773","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:19:27Z","timestamp":1768436367000},"page":"103773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Analysis of Patients With C3 Glomerulopathy in the United States"],"prefix":"10.1016","volume":"11","author":[{"given":"Briana C.","family":"Ndife","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Aldworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Pivneva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Louise","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro A.","family":"Canetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.103773_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy \u2013 understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.103773_bib2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.kint.2017.10.022","article-title":"C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy","volume":"93","author":"Bomback","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.103773_bib3","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000507254","article-title":"Update on C3 glomerulopathy: a complement-mediated disease","volume":"144","author":"Caravaca-Font\u00e1n","year":"2020","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2026.103773_bib4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1053\/j.akdh.2024.05.002","article-title":"Update on C3 glomerulopathy","volume":"31","author":"Wooden","year":"2024","journal-title":"Adv Kidney Dis Health"},{"key":"10.1016\/j.ekir.2026.103773_bib5","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"issue":"6 Suppl 1","key":"10.1016\/j.ekir.2026.103773_bib6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3949\/ccjm.90.e-s1.01","article-title":"C3 glomerulopathy","volume":"90","author":"Mehdi","year":"2023","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.ekir.2026.103773_bib7","series-title":"C3 Glomerulopathy","article-title":"In: GeneReviews\u00ae","author":"Mart\u00edn","year":"2015"},{"key":"10.1016\/j.ekir.2026.103773_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ekir.2024.10.008","article-title":"Outcome of patients transplanted for C3 glomerulopathy and primary immune complex-mediated membranoproliferative glomerulonephritis","volume":"10","author":"Halfon","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.103773_bib9","doi-asserted-by":"crossref","first-page":"632","DOI":"10.5500\/wjt.v6.i4.632","article-title":"Complement related kidney diseases: recurrence after transplantation","volume":"6","author":"Salvadori","year":"2016","journal-title":"World J Transplant"},{"key":"10.1016\/j.ekir.2026.103773_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.04700513","article-title":"C3 glomerulopathy: clinicopathologic features and predictors of outcome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.103773_bib11","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1053\/j.ajkd.2018.09.002","article-title":"Kidney transplantation in C3 glomerulopathy: a case series","volume":"73","author":"Regunathan-Shenk","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.103773_bib12","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.103773_bib14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ekir.2023.12.007","article-title":"C3 glomerulopathy: novel treatment paradigms","volume":"9","author":"Tarragon Estebanez","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.103773_bib16","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ndt\/gfab075","article-title":"Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy","volume":"37","author":"Caravaca-Font\u00e1n","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.103773_bib17","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/ki.2015.227","article-title":"Effectiveness of mycophenolate mofetil in C3 glomerulonephritis","volume":"88","author":"Rabasco","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.103773_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome","volume":"71","author":"Iatropoulos","year":"2016","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ekir.2026.103773_bib19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000479012","article-title":"Immunosuppressive treatment in C3 glomerulopathy: is it really effective?","volume":"46","author":"Caliskan","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2026.103773_bib20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40620-019-00672-5","article-title":"Outcome of C3 glomerulopathy patients: largest single-centre experience from South Asia","volume":"33","author":"Kumar","year":"2020","journal-title":"J Nephrol"},{"key":"10.1016\/j.ekir.2026.103773_bib21","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1093\/ckj\/sfac108","article-title":"Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy","volume":"15","author":"Caravaca-Font\u00e1n","year":"2022","journal-title":"Clin Kidney J"},{"issue":"Suppl 1","key":"10.1016\/j.ekir.2026.103773_bib22","first-page":"gfae069","article-title":"#1011 Clinical characteristics and outcomes of C3 glomerulopathy and immune complex MPGN from the UK National Registry of Rare Kidney Diseases (RaDaR)","volume":"39","author":"Masoud","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.103773_bib23","doi-asserted-by":"crossref","first-page":"659","DOI":"10.34067\/KID.0000000000000115","article-title":"Clinical profiles and patterns of kidney disease progression in C3 glomerulopathy","volume":"4","author":"Caravaca-Font\u00e1n","year":"2023","journal-title":"Kidney360"},{"key":"10.1016\/j.ekir.2026.103773_bib24","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.mayocp.2018.05.019","article-title":"C3 glomerulopathy: ten years\u2019 experience at Mayo Clinic","volume":"93","author":"Ravindran","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ekir.2026.103773_bib26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/10408363.2020.1723487","article-title":"Diagnostic utility of protein to creatinine ratio (P\/C ratio) in spot urine sample within routine clinical practice","volume":"57","author":"Kami\u0144ska","year":"2020","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.ekir.2026.103773_bib27","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/JU.0000000000001297","article-title":"Microhematuria: AUA\/SUFU guideline","volume":"204","author":"Barocas","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.ekir.2026.103773_bib28","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2215\/CJN.00910121","article-title":"Recurrence of IgA nephropathy after kidney transplantation in adults","volume":"16","author":"Uffing","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.103773_bib29","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1681\/ASN.2013070715","article-title":"Clinical findings, pathology, and outcomes of C3GN after kidney transplantation","volume":"25","author":"Zand","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.103773_bib30","first-page":"44","article-title":"Treatment of C3 glomerulopathy in adult kidney transplant recipients: a systematic review","volume":"8","author":"Gonzalez Suarez","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.ekir.2026.103773_bib31","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1159\/000527167","article-title":"Clinical outcomes of patients with C3G or IC-MPGN treated with the factor D inhibitor danicopan: final results from two phase 2 studies","volume":"53","author":"Nester","year":"2022","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2026.103773_bib32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1681\/ASN.0000000526","article-title":"Safety and efficacy of avacopan in patients with complement 3 glomerulopathy: randomized, double-blind clinical trial","volume":"36","author":"Bomback","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.103773_bib38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nrneph.2014.217","article-title":"Histopathology of MPGN and C3 glomerulopathies","volume":"11","author":"Cook","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.103773_bib39","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926000045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926000045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:05:04Z","timestamp":1777633504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926000045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2468024926000045"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.103773","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Analysis of Patients With C3 Glomerulopathy in the United States","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.103773","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103773"}}